WORCESTER, Mass., Oct. 15, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today an update from its Middle Eastern master licensee, Leosons General Trading Company, a leading distributor of North American healthcare products in the region, on the status of regulatory filings for Generex Oral-lyn(tm), the Company’s proprietary oral insulin spray product.
